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INTRODUCTION
The complement system is a biochemical cascade which
helps clear pathogens from a host organism. However, the
complement system also has the potential to be extremely
detrimental to host tissues, meaning its activation must be
tightly regulated to prevent developing inflammatory reac-
tions (1). Complement 1 (C1) inhibitor is a naturally occur-
ring serine proteinase inhibitor that inhibits activated serine
proteinases, C1s and C1r, from the classical pathway of com-
plement, and is a main inhibitor of activated factor FXII from
the contact system, and also is an inhibitor of kallikrein and
activated factor XI (2). Furthermore, C1 inhibitor is an acute
phase protein, the plasma level of which may increase 2- to
2.5-fold during an inflammatory condition, such as an infec-
tion or rheumatoid arthritis (3, 4). Arteriolosclerosis or arte-
rial stiffness is any hardening of arteries due to loss of elastic-
ity. On the other hand, atherosclerosis is an inflammatory dis-
ease of the artery and shows hardening of artery specifically
due to an atheromatous plaque (5-8). Atherosclerosis is the
most common form of arteriosclerosis, thus the risk factors
of both are similar (6, 7). Recently it has been reported that
arterial stiffness is strongly associated with atherosclerosis and
accelerated by risk factors such as aging, hypertension, dia-
betes, and renal insufficiency (6, 7, 9). The non-invasive test
for arterial stiffness, brachial ankle pulse wave velocity (ba-
PWV), is used in large scale populations and has become avai-
lable in clinical settings (10). As arterial stiffness is closely rel-
ated to atherosclerosis, an inflammatory disease of arterial wall
(9, 11), we postulated that if the arterial stiffness is progress-
ing, the inflammation of the arterial wall will corresponding-
ly deteriorate. Thus, we hypothesize that if baPWV increas-
es, the serum level of the acute phase protein, C1 inhibitor,
may also rise to counteract the inflammation. To investigate
this hypothesis, we measured baPWV and C1 inhibitor. At
the same time, to evaluate the clinical relevance of baPWV,
we also measured the conventional risk factors of arterioscle-
rosis and/or atherosclerosis (6-8, 12), such as age, gender, hy-
pertension, smoking, body mass index (BMI), total choleste-
rol, low-density lipoprotein (LDL), high-density lipoprotein
(HDL), triglycerides (TG), hemoglobin A1c (HbA1c), and
the parameters of inflammation (erythrocyte sedimentation
rate [ESR], C-reactive protein [CRP], and C3).
MATERIALS AND METHODS
Study population
One hundred consecutive subjects, 18-77 yr of age, from
the Department of Surgery of our hospital were enrolled in
this study between June and December 2008, and analyzed
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Complement 1 (C1) inhibitor is an acute phase protein with anti-inflammatory prop-
erties. The aim of the present study was to elucidate the relationship between bra-
chial ankle pulse wave velocity (baPWV), the parameter of arterial stiffness, and C1
inhibitor. One hundred subjects were randomly enrolled in this study. Data about
baPWV, age, gender, hypertension, smoking, and body mass index (BMI) were mea-
sured. Blood tests for total cholesterol, low density lipoprotein, high density lipopro-
tein, triglycerides, hemoglobin A1c, erythrocyte sedimentation rate, C-reactive pro-
tein, complement 3, and C1 inhibitor were performed. Based on the Pearson cor-
relation, the C1 inhibitor showed a positive relation to the baPWV (P<0.001). Multi-
ple regression analysis revealed the significant predictors of baPWV were not only
the conventional risk factors of arteriosclerosis and/or atherosclerosis, such as age
(P<0.001), gender (P<0.001), hypertension (P<0.001), and BMI (P=0.006), but also
the acute phase protein, C1 inhibitor (P=0.025). In conclusion, C1 inhibitor is associ-
ated with arterial stiffness through its association with increased inflammation.
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Accepted : 25 June 2009cross-sectionally at the end of the study. All the subjects were
enrolled voluntarily and randomly without any inclusion or
exclusion criteria, however all the patients had surgical dis-
eases such as varicose vein, hemorrhoid, and inguinal hernia
(Table 1). A total of 40.5% of male (17/42) and 20.7% of fe-
male (12/58) patients had hypertension. They had calcium
channel blocker (14 patients), angiotensin-2 receptor inhibitor
(10 patients), beta blocker (4 patients), and diuretics (1 pati-
ent). A total of 19% of male (8/42) and 13.8% of female (8/
58) patients had diabetes, and all of them administered oral
hypoglycemic agents. Two patients with hypercholesterolemia
had HMG CoA reductase inhibitor. In this study, hyperten-
sion was defined as a systolic blood pressure ≥140 mmHg
and a diastolic pressure ≥90 mmHg, or for the subject who
was taking antihypertensive medications, regardless of the
current pressure. Smokers included the subjects who were
smoking at the time of the measurement and ex-smokers.
BMI was calculated as the body weight in kilograms divid-
ed by the height in meters squared. Informed consent was
obtained from all the subjects. This study was approved by
the Institutional Review Board of Masan Samsung Hospital
of Sungkyunkwan University School of Medicine in Masan,
Korea.
Blood samples
Blood samples were obtained from an antecubital vein in
the morning after 12 hr of overnight fasting. An automatic
analyzer (Modular System; Roche, Mannheim, Germany) was
used to measure total cholesterol, LDL, HDL, and TG. HbA1c
was measured by an automatic machine (HLC723-G7; TO-
SOH, Tokyo, Japan). CRP and C3 were analyzed by an auto-
matic analyzer (COBAS Integra 800; Roche, Rotkreuz, Swiss).
C1 inhibitor was measured using a kit (C1 inactivator; RID,
San Diego, CA, U.S.A.). ESR was measured manually with
the Wintrobe tube method (Espette, Kormed, Seoul, Korea).
Instrument and assessment of inter-observer and 
intra-observer reliability
The baPWV was measured by a volume plethysmograph-
ic apparatus (Vasoguard, model P84; Nicolet Vascular, Gold-
en, CO, U.S.A.). For the assessment of inter-observer reliabili-
ty (reproducibility) and intra-observer reliability (repeatabili-
ty), 10 volunteers (5 males and 5 females; 26-67 yr of age ran-
ge; mean age, 45 yr; 95% CI, 34-56 yr) were measured con-
secutively by 3 observers (technicians of the vascular labora-
tory) with 10 min intervals. Cuffs were rewrapped at every
measurement. The same measurements were repeated the
next day; hence there were a total of 60 measurements. All
the measurements were performed in the morning after over-
night fasting. To obtain the reproducibility and repeatabili-
ty of measuring baPWV by Vasoguard, the intraclass corre-
lation coefficient (ICC) was calculated using the data of the
right baPWV of the volunteers.
Brachial ankle pulse wave velocity
In this study, 100 subjects were examined for baPWV in
the morning after 10 min of rest in a temperature-controlled
warm room (24±1℃). They did not take any medications
on the day of the examination. Measurements were performed
in the supine position. Waveforms were obtained from vol-
ume plethysmographic sensors in cuffs on the right brachi-
um and both ankles. The time intervals ( Tba) between the
wave at the right brachium and at both ankles were record-
ed automatically by the machine. The distance between the
sampling points of baPWV was calculated using the follow-
ing equations: the length from the suprasternal notch to the
right brachium (Lb)=0.2195×height (cm)-2.0734, and the
length from the suprasternal notch to the ankle (La)=0.8129
×height (cm)+12.328. The baPWV=(La-Lb)/ Tba (10).
The average values of the right and left baPWVs were used
in the statistical analysis. 
Statistics
Intraclass correlation coefficient (ICC) was calculated by
SAS (version 9.1; SAS Institute Inc., Cary, NC, U.S.A.). ICC
values <0.4 represent poor reliability, and ICC values between
0.4 and 0.75 indicate fair-to-good reliability, whereas an ICC
value >0.75 represents excellent reliability (13). The relation
between C1 inhibitor and other inflammatory markers was
tested by Spearman Correlation. The age distribution was test-
ed by the Kolmogorov-Smirnov test of normality. The differ-
ences between males and females were compared by an inde-
pendent sample t-test and the chi-square test. The univariate
analysis between baPWV and age, BMI, total cholesterol,
LDL, HDL, TG, HbA1c, C1 inhibitor, C3, ESR, and CRP
was performed by Pearson and Spearman Correlation depend-
ing on the distribution patterns of the variables. Using the
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Diseases Number
Varicose vein 24
Hemorrhoid 18
Inguinal hernia 16
Gallbladder stone 11
Atherosclerosis of extremity 4
Buerger’s disease 3
Sebaceous cyst 3
Breast fibroadenoma 6
Gastric ulcer 1
Thyroid cancer 8
Breast cancer 2
Colon cancer 2
Stomach cancer 1
Gallbladder cancer 1
Table 1. The surgical diseases of the patientsindependent sample t-test, the differences of baPWV were
measured as a function of gender, smoking, and hypertension.
Multiple regression analysis using the stepwise method was
performed to identify the predictors of baPWV. The indepen-
dent variables included in the multiple regression analysis
were age, gender, hypertension, BMI, total cholesterol, TG,
HbA1c, C3, ESR, CRP, and C1 inhibitor. LDL, HDL choles-
terol, and smoking were not included in the multiple regres-
sion analysis, because LDL and HDL cholesterol showed mul-
ticollinearity with total cholesterol (VIF 13.84, 3.40, and 15.19
respectively), and there were marked difference in smoking
rate between males (80.9%, 34/42) and females (1.7%, 1/58).
Statistical analysis was done using SPSS (version 11.5; SPSS
Inc., Chicago, IL, U.S.A.). P values <0.05 were considered
statistically significant.
RESULTS
Inter-observer and intra-observer reliability, calculated by
the ICC were 0.8783 and 0.8927, respectively, thus indicat-
ing that measuring baPWV with the Vasoguard machine has
excellent reproducibility and repeatability (Fig. 1). The nor-
mality assumption for the distribution of age for 100 subjects
and for males and females were not rejected by Kolmogorov-
Smirnov test (P value=0.200, 0.110, and 0.200, respectively).
The mean and 95% confidence interval of age for 100 subjects
were 47.81 and 44.92-50.70 yr, and its values ranged from
18 to 77. There was no age difference between the males and
females (Table 2); however, the smoking habit (male 80.9%
vs. female 1.7%) and hypertension rate (male 40.5% vs. female
20.7%) were higher in males than females (P value <0.001
and 0.044, respectively by chi-square test). Fig. 2 depicts that
baPWVs increase in proportion to the advancing age in both
males and females. In Table 3, male gender, smokers, and
hypertensive subjects had higher baPWVs than females, non-
smokers, and non-hypertensive subjects. The univariate anal-
ysis indicated that baPWV had a positive correlation with
age, BMI, TG, HbA1c, C1 inhibitor, C3, and CRP; howev-
er, HDL had a negative correlation (Table 4). The multiple
regression analysis (stepwise method) showed not only the
conventional risk factors of arteriosclerosis and/or atheroscle-
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Independent sample t-test; P<0.05 is significant.
CI, confidence interval; BMI, body mass index; LDL, low density lipopro-
tein; HDL, high density lipoprotein; TG, triglycerides; HbA1c, hemoglobin
A1c; C1, complement 1; C3, complement 3; ESR, erythrocyte sedimen-
tation rate; CRP, C-reactive protein. 
Male Female
P value
Mean 95% CI Mean 95% CI
Age (yr) 50 45-55 45 42-49 0.098
BMI (kg/m
2) 23 22-23 22 22-23 0.640
Total cholesterol 176 166-186 183 173-192 0.336
(mg/dL)
LDL (mg/dL) 103 94-113 109 101-117 0.361
HDL (mg/dL) 46 42-50 52 48-55 0.021
TG (mg/dL) 153 120-187 112 96-128 0.016
HbA1C (%) 5.63 5.46-5.80 5.48 5.33-5.63 0.184
C1 inhibitor (mg/dL) 25 23-26 24 23-25 0.567
C3 (mg/dL) 113 109-117 112 107-117 0.814
ESR (mm/hr) 10 6-13 16 13-19 0.008
CRP (mg/L) 1.91 1.20-2.61 1.89 0.99-2.79 0.976
Table 2. The difference of clinical characteristics between the
male and female participants
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Fig. 1. Inter-observer and intra-observer reliability of measurements of the brachial ankle pulse wave velocity (cm/sec). (A) Inter-observer
reliability (reproducibility) depicts the relationship between three independent measurements by three observers, r1 (observer 1), r2 (observ-
er 2), and r3 (observer 3). The ICC value is 0.8783. (B) Intra-observer reliability (repeatability) shows the relationship between two differ-
ent measurements by one observer. The ICC value is 0.8927.
Variablesrosis, such as age, gender, hypertension, and BMI but also
the acute phase protein, C1 inhibitor, was a significant pre-
dictor of baPWV (Table 5, Fig. 3). C1 inhibitor revealed pos-
itive correlation with other inflammatory markers, C3 and
CRP (Table 6).
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Variables Coefficient P value
Age 0.713 <0.001*
BMI 0.362  <0.001*
Total cholesterol 0.070 0.484*
LDL 0.037 0.710*
HDL -0.243 0.014
�
TG 0.349 <0.001
�
HbA1C 0.414 <0.001
�
C1 inhibitor 0.329  <0.001*
C3 0.329 <0.001*
ESR 0.129 0.199
�
CRP 0.324 <0.001
�
Table 4. Univariate analysis between brachial ankle pulse wave
velocity and the variables 
*Pearson correlation (Variables have normal distribution.); 
� Spearman cor-
relation (Variables do not have normal distribution.); P<0.05 is significant.
BMI, body mass index; LDL, low density lipoprotein; HDL, high density
lipoprotein; TG, triglycerides; HbA1c, hemoglobin A1c; C1, complement
1; C3, complement 3; ESR, erythrocyte sedimentation rate; CRP, C-reac-
tive protein.
Variables Regression coefficient P value R
2
Constant 657.06 <0.001 0.695
Age 7.365 <0.001
Gender -137.521 <0.001
Hypertension -143.066 <0.001
BMI 14.605 0.006
C1 inhibitor 6.367 0.025
Table 5. Predictors for brachial ankle pulse wave velocity in mul-
tiple regression analysis
Multiple regression analysis (stepwise method); gender (male=1, female=
2); hypertension (yes=1, no=2); P<0.05 is significant.
BMI, body mass index; C1, complement 1. 
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Fig. 2. Linear regression graphs between baPWV and age in both males and females. (A) male, (B) female, baPWVs increase in propor-
tion to the age in both males and females.
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Fig. 3. Linear regression graph between baPWV and C1 inhibitor. 
Brachial ankle pulse wave velocity showed positive relationship to
the serum level of C1 inhibitor. baPWV increases according to the
increasing serum level of C1 inhibitor.
Independent-sample t-test; P<0.05 is significant.
Variables Number
Mean
(cm/sec)
95% CI
(cm/sec)
P value
Gender Male 42 1,161 1,097-1,226 <0.001
Female 58 952 888-1,015
Smoking Yes 35 1,126 1,054-1,198 0.010
No 65 993 929-1,057
Hypertension Yes 29 1,288 1,222-1,354 <0.001
No 71 938 891-985
Table 3. Comparison of brachial ankle pulse wave velocity as a
function of gender, smoking, and hypertensionDISCUSSION
In the current study, baPWV had a significant association
with the conventional risk factors of arteriosclerosis and/or
atherosclerosis, such as age, gender, hypertension, and BMI
in both univariate and multivariate studies. This means that
baPWV is a clinically relevant method to evaluate the arter-
ies, and this result is compatible with the other studies on
the relation between baPWV and risk factors (6, 7, 10, 14,
15). According to our hypothesis, we measured the relative-
ly novel inflammatory marker, C1 inhibitor. In the result, the
serum level of C1 inhibitor was positively related to baPWV,
and C1 inhibitor was one of the significant predictors of ba-
PWV. The serine proteinase inhibitor, C1 inhibitor, is syn-
thesized and secreted from the several cell types, including
hepatocytes, mononuclear phagocytes, fibroblasts, and umbil-
ical vein endothelial cells (16-18). The major function of the
C1 inhibitor is inhibition of the complement system to pre-
vent spontaneous activation, in which the amount of C1 in-
hibitor in the serum is crucial. A minimal C1 inhibitor con-
centration of approximately 5.5 mg/dL (22% of the normal
human serum level) is required to control C1-autoactivation
(19). Originally, C1 inhibitor was shown to be associated with
angioedema, and its deficiency was identified as the cause of
hereditary angioedema (20, 21). However, C1 inhibitor be-
longs to a group of acute phase proteins, and its production
and release increase during inflammation (3, 4). In our study,
C1 inhibitor revealed positive correlation with C3 and CRP,
thus indicating that C1 inhibitor was a member of acute phase
proteins. Recently, it has been suggested that all the risk fac-
tors of atherosclerosis contribute to the development of athe-
rosclerosis by aggravating the underlying inflammatory pro-
cess (5, 8, 9, 11, 22-25). Although the exact mechanism is
unknown, it has been reported that the inflammatory cyto-
kine, interferon-gamma (IFN-gamma) is highly expressed
in atherosclerotic lesions (26), moreover, IFN-gamma also
enhances the expression of C1 inhibitor mRNA, primarily
due to an enhanced transcription rate (27). Other cytokines,
such as tumor necrosis factor alpha, interferon-alpha, mono-
cyte colony stimulating factor, and interleukin-6 were also
identified to stimulate the synthesis of C1 inhibitor (2). De-
termination of baPWV involves a simple and non-invasive
method, and its validity, reproducibility, and clinical signif-
icance have been evaluated and confirmed in a previous study
(10). In this study, we also demonstrated that the reproduci-
bility and repeatability of measuring baPWV with Vasoguard
equipment is reliable. In recent years, baPWV has been used
more widely in assessing arterial stiffness, and has become
available in a clinical setting as a simple predictor of the prog-
nosis of patients (9, 14, 15, 28-30). In current study, we mea-
sured baPWV as a parameter of arterial stiffness and C1 in-
hibitor as a counteracting anti-inflammatory substance. Our
result showed that baPWV had positive relation with C1 in-
hibitor; the higher the baPWV, the greater the serum level
of C1 inhibitor. In summary, C1 inhibitor was positively relat-
ed to baPWV, and was one of the significant predictors of ba-
PWV. The present study suggests that C1 inhibitor is asso-
ciated with arterial stiffness through its association with incre-
ased inflammation.
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